Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study.
暂无分享,去创建一个
P. Ruszniewski | M. Pavel | L. Wall | G. Rindi | M. Raderer | J. Capdevila | M. Caplin | E. Wolin | A. Phan | G. Cadiot | E. Sedláčková | E. Gomez-Panzani | A. Langley | J. Cwikła